Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

2021-02-26T19:12:23-08:00May 8th, 2018|2018 Press Releases, Press Releases|